A detailed history of Met Life Investment Management, LLC transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 22,729 shares of MIRM stock, worth $1.01 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
22,729
Previous 22,729 -0.0%
Holding current value
$1.01 Million
Previous $777,000 14.03%
% of portfolio
0.01%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$23.57 - $34.85 $202,796 - $299,849
8,604 Added 60.91%
22,729 $777,000
Q1 2024

May 14, 2024

BUY
$24.92 - $30.02 $351,995 - $424,032
14,125 New
14,125 $354,000
Q4 2023

Feb 14, 2024

BUY
$27.14 - $34.93 $885,523 - $1.14 Million
32,628 Added 230.99%
46,753 $1.38 Million
Q3 2023

May 09, 2024

BUY
$24.63 - $32.85 $127,657 - $170,261
5,183 Added 57.96%
14,125 $446,000
Q2 2023

Apr 29, 2024

BUY
$23.51 - $30.09 $332,078 - $425,021
14,125 New
14,125 $365,000
Q2 2023

Aug 10, 2023

BUY
$23.51 - $30.09 $121,852 - $155,956
5,183 Added 57.96%
14,125 $365,000
Q1 2023

May 09, 2024

BUY
$19.19 - $24.1 $171,596 - $215,502
8,942 New
8,942 $215 Million
Q1 2023

May 15, 2023

BUY
$19.19 - $24.1 $9,863 - $12,387
514 Added 6.1%
8,942 $214,000
Q4 2022

Jun 14, 2023

SELL
$17.59 - $23.83 $9,041 - $12,248
-514 Reduced 5.75%
8,428 $164,000
Q3 2022

Jun 14, 2023

SELL
$19.98 - $29.44 $10,269 - $15,132
-514 Reduced 5.75%
8,428 $177,000
Q2 2022

May 10, 2024

BUY
$18.42 - $27.5 $155,243 - $231,770
8,428 New
8,428 $164,000
Q2 2022

Jun 20, 2023

SELL
$18.42 - $27.5 $9,467 - $14,135
-514 Reduced 5.75%
8,428 $164,000
Q2 2022

Aug 11, 2022

BUY
$18.42 - $27.5 $155,243 - $231,770
8,428 New
8,428 $164,000

Others Institutions Holding MIRM

About Mirum Pharmaceuticals, Inc.


  • Ticker MIRM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,751,700
  • Market Cap $1.64B
  • Description
  • Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...
More about MIRM
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.